Cargando…

Advances in the Pharmacological Management of Diabetic Nephropathy: A 2022 International Update

Diabetic nephropathy (DN) is the leading cause of end-stage renal disease (ESRD) worldwide. Its pathogenesis encompasses functional alterations involving elevated intraglomerular and systemic pressure, increased activity of the renin-angiotensin system (RAS) and oxidative stress, and the eventual de...

Descripción completa

Detalles Bibliográficos
Autores principales:	Giglio, Rosaria Vincenza, Patti, Angelo Maria, Rizvi, Ali Abbas, Stoian, Anca Panta, Ciaccio, Marcello, Papanas, Nikolaos, Janez, Andrej, Sonmez, Alper, Banach, Maciej, Sahebkar, Amirhossein, Rizzo, Manfredi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9953496/ https://www.ncbi.nlm.nih.gov/pubmed/36830828 http://dx.doi.org/10.3390/biomedicines11020291

Ejemplares similares

An Update on the Current and Emerging Use of Thiazolidinediones for Type 2 Diabetes
por: Giglio, Rosaria Vincenza, et al.
Publicado: (2022)

Novel Therapeutical Approaches to Managing Atherosclerotic Risk
por: Giglio, Rosaria Vincenza, et al.
Publicado: (2021)

Experimental and Emerging Free Fatty Acid Receptor Agonists for the Treatment of Type 2 Diabetes
por: Patti, Angelo Maria, et al.
Publicado: (2022)

Use of Novel Antidiabetic Agents in Patients with Type 2 Diabetes and COVID-19: A Critical Review
por: Popovic, Djordje S., et al.
Publicado: (2021)

Liraglutide Improved Cardiometabolic Parameters More in Obese than in Non-obese Patients with Type 2 Diabetes: A Real-World 18-Month Prospective Study
por: Nikolic, Dragana, et al.
Publicado: (2022)

Effect of Semaglutide on Subclinical Atherosclerosis and Cardiometabolic Compensation: A Real-World Study in Patients with Type 2 Diabetes
por: Patti, Angelo Maria, et al.
Publicado: (2023)

Lipoproteins and Cardiovascular Disease: An Update on the Clinical Significance of Atherogenic Small, Dense LDL and New Therapeutical Options
por: Rizvi, Ali A., et al.
Publicado: (2021)

Atherosclerosis Development and Progression: The Role of Atherogenic Small, Dense LDL
por: Vekic, Jelena, et al.
Publicado: (2022)

Liraglutide Reduces Carotid Intima-Media Thickness by Reducing Small Dense Low-Density Lipoproteins in a Real-World Setting of Patients with Type 2 Diabetes: A Novel Anti-Atherogenic Effect
por: Nikolic, Dragana, et al.
Publicado: (2020)

Impact of Glucose-Lowering Medications on Cardiovascular and Metabolic Risk in Type 2 Diabetes
por: Patti, Angelo Maria, et al.
Publicado: (2020)

Pasta Supplemented with Opuntia ficus-indica Extract Improves Metabolic Parameters and Reduces Atherogenic Small Dense Low-Density Lipoproteins in Patients with Risk Factors for the Metabolic Syndrome: A Four-Week Intervention Study
por: Giglio, Rosaria Vincenza, et al.
Publicado: (2020)

Management of Statin Intolerance in 2018: Still More Questions Than Answers
por: Toth, Peter P., et al.
Publicado: (2018)

Diabetes and Colorectal Cancer Risk: A New Look at Molecular Mechanisms and Potential Role of Novel Antidiabetic Agents
por: Vekic, Jelena, et al.
Publicado: (2021)

The Dual Pandemics of COVID-19 and Obesity: Bidirectional Impact
por: Kapoor, Nitin, et al.
Publicado: (2022)

A Critical View over the Newest Antidiabetic Molecules in Light of Efficacy—A Systematic Review and Meta-Analysis
por: Salmen, Teodor, et al.
Publicado: (2023)

Personalized management of dyslipidemias in patients with diabetes—it is time for a new approach (2022)
por: Banach, Maciej, et al.
Publicado: (2022)

Metabolic disorders during pregnancy and postpartum cardiometabolic risk
por: Patti, Angelo Maria, et al.
Publicado: (2018)

Molecular and pro-inflammatory aspects of COVID-19: The impact on cardiometabolic health
por: Lo Presti, Elena, et al.
Publicado: (2022)

Telemedicine for diabetes management during COVID-19: what we have learnt, what and how to implement
por: Rosta, Laszlo, et al.
Publicado: (2023)

Effect of Oral Semaglutide on Cardiovascular Parameters and Their Mechanisms in Patients with Type 2 Diabetes: Rationale and Design of the Semaglutide Anti-Atherosclerotic Mechanisms of Action Study (SAMAS)
por: Janić, Miodrag, et al.
Publicado: (2022)

Liraglutide Increases Serum Levels of MicroRNA-27b, -130a and -210 in Patients with Type 2 Diabetes Mellitus: A Novel Epigenetic Effect
por: Giglio, Rosaria Vincenza, et al.
Publicado: (2020)

Daily Use of Extra Virgin Olive Oil with High Oleocanthal Concentration Reduced Body Weight, Waist Circumference, Alanine Transaminase, Inflammatory Cytokines and Hepatic Steatosis in Subjects with the Metabolic Syndrome: A 2-Month Intervention Study
por: Patti, Angelo M., et al.
Publicado: (2020)

Current Pharmacological Treatment of Painful Diabetic Neuropathy: A Narrative Review
por: Ardeleanu, Valeriu, et al.
Publicado: (2020)

Metabolic Syndrome: From Molecular Mechanisms to Novel Therapies
por: Rizvi, Ali Abbas, et al.
Publicado: (2021)

Cardiometabolic Alterations in the Interplay of COVID-19 and Diabetes: Current Knowledge and Future Avenues
por: Rizvi, Ali A., et al.
Publicado: (2021)

Associations between Periodontitis, COVID-19, and Cardiometabolic Complications: Molecular Mechanisms and Clinical Evidence
por: Mainas, Giuseppe, et al.
Publicado: (2022)

Diabetes, Vascular Aging and Stroke: Old Dogs, New Tricks?
por: Penlioglou, Theano, et al.
Publicado: (2021)

The potential role of mitochondrial ATP synthase inhibitory factor 1 (IF1) in coronary heart disease: a literature review
por: Maierean, Serban, et al.
Publicado: (2017)

Endocrinology in the Time of COVID-19: A Rapid Evolution of Knowledge and Care
por: Rizvi, Ali A., et al.
Publicado: (2021)

New-Onset Diabetes in COVID-19: Time to Frame Its Fearful Symmetry
por: Papachristou, Stella, et al.
Publicado: (2020)

Post-COVID syndrome, inflammation, and diabetes()
por: Rizvi, Ali A., et al.
Publicado: (2022)

The Role of Fructose as a Cardiovascular Risk Factor: An Update
por: Busnatu, Stefan-Sebastian, et al.
Publicado: (2022)

Novel Pharmaceutical and Nutraceutical-Based Approaches for Cardiovascular Diseases Prevention Targeting Atherogenic Small Dense LDL
por: Vekic, Jelena, et al.
Publicado: (2022)

The Effects of Sodium-Glucose Cotransporter 2-Inhibitors on Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease or Steatohepatitis and Type 2 Diabetes: A Systematic Review of Randomized Controlled Trials
por: Bica, Ioana-Cristina, et al.
Publicado: (2023)

The Relationship between COVID-19 and Hypothalamic–Pituitary–Adrenal Axis: A Large Spectrum from Glucocorticoid Insufficiency to Excess—The CAPISCO International Expert Panel
por: Jensterle, Mojca, et al.
Publicado: (2022)

Liraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome: an 18-month prospective study
por: Rizzo, Manfredi, et al.
Publicado: (2016)

New Sub-Phenotyping of Subjects at High Risk of Type 2 Diabetes: What Are the Potential Clinical Implications?
por: Popovic, Djordje S., et al.
Publicado: (2021)

The Evolving Role of Fetuin-A in Nonalcoholic Fatty Liver Disease: An Overview from Liver to the Heart
por: Dogru, Teoman, et al.
Publicado: (2021)

Natural approaches in metabolic syndrome management
por: Patti, Angelo Maria, et al.
Publicado: (2017)

Response letter: Management of statin‐induced myopathies: Much demands and still (almost) empty hands!
por: Sahebkar, Amirhossein, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_0knehuqgcketbkkfcq9lsttmbp